Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 7/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL14334475 | 0.98 | TAAR1 (0.41) | TAAR1KDM4ELMNAMAPK1HTR2A | |
| SCHEMBL21931379 | 0.84 | KIF11 (0.54) | KIF11 | |
| SCHEMBL569409 | 0.82 | HRH1 (0.46) | TAAR1KDM4ELMNAMAPK1HTR2A | |
| SCHEMBL27443281 | 0.79 | ANPEP (0.43) | TAAR1KDM4ELMNAMAPK1KIF11 | |
| SCHEMBL6655141 | 0.79 | KDM4E (0.46) | TAAR1KDM4ELMNAMAPK1KIF11 | |
| SCHEMBL2390381 | 0.79 | HRH1 (0.50) | TAAR1KDM4ELMNAMAPK1HTR2A | |
| SCHEMBL9768637 | 0.77 | TAAR1 (0.50) | TAAR1KDM4ELMNAMAPK1HTR2A | |
| SCHEMBL1619121 | 0.77 | TAAR1 (0.50) | TAAR1KDM4ELMNAMAPK1HTR2A | |
| Hydrochloric Acid SCHEMBL7066884 | 0.76 | TAAR1 (0.48) | TAAR1KDM4ELMNAMAPK1HTR2A | |
| SCHEMBL914102 | 0.76 | KDM4E (0.39) | TAAR1KDM4ELMNAMAPK1KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709424-A1 | LYOPHILIZED PRODUCTS, PHARMACEUTICAL COMPOSITIONS, AND KITS COMPRISING DYE-PEPTIDE CONJUGATES AND DERIVATIVES | Integro Theranostics, LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024233672-A1 | LYOPHILIZED PRODUCTS, PHARMACEUTICAL COMPOSITIONS, AND KITS COMPRISING DYE-PEPTIDE CONJUGATES AND DERIVATIVES | INTEGRO THERANOSTICS, LLC (US) | 2024-11-14 | — | — | WO | disclosed |
| WO-2024112201-A1 | DNA GYRASE INHIBITORS | UNIVERSITEIT LEIDEN (NL) | 2024-05-30 | — | — | WO | disclosed |
| EP-4323017-A1 | FOLATE RECEPTOR-TARGETED RADIOTHERAPEUTIC AGENTS AND THEIR USE | Novartis AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| CN-117083088-A | Folate receptor targeted radiotherapy agent and use thereof | 诺华股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| WO-2023072971-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| EP-4170347-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2023-04-26 | — | — | EP | disclosed |
| US-20230040236-A1 | Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications | PALATIN TECHNOLOGIES, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| CN-115551555-A | Methods, compounds, and compositions for modifying CAR-T cell activity | 普渡研究基金会 | 2022-12-30 | — | — | CN | disclosed |
| CN-115515617-A | Diamine-linked receptor-specific cyclic peptides | 帕拉丁科技公司 | 2022-12-23 | — | — | CN | disclosed |
| WO-2001098278-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | CYTOKINETICS, INC. (US) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001096343-A1 | SUBSTITUTED METAL-PHTHALOCYANINES, THEIR PREPARATION AND THE USE THEREOF | L. MOLTENI & C. DEI FRATELLI ALITTI - SOCIETÀ DI ESERCIZIO S.P.A. (IT) | 2001-12-20 | — | — | WO | disclosed |
| EP-1164135-A1 | Substituted metal-phthalocyanines, their preparation and the use thereof | L. MOLTENI & C. DEI FRATELLI ALITTI SOCIETA' DI ESERCIZIO SOCIETA' PER AZIONI (IT) | 2001-12-19 | — | — | EP | disclosed |
| WO-2001052898-A1 | METHODS FOR INCORPORATING METAL CHELATORS AT CARBOXYL-TERMINAL SITE OF PEPTIDES | MALLINCKRODT INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| WO-2001030768-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | CYTOKINETICS, INC. (US) | 2001-05-03 | — | — | WO | disclosed |
| EP-0983290-A1 | METHOD FOR PRODUCING POLYMERS HAVING NUCLEO-BASES AS SIDE-GROUPS | Morphochem AG (DE) | 2000-03-08 | — | — | EP | disclosed |
| US-5965598-A | PHOTOTHERAPEUTIC AND PHOTODIAGNOSTIC AGENTS AS FREE MOLECULES AND AS CONJUGATES WITH MACROMOLECULAR CARRIER MOLECULES | MOLTENI L. & C. DEI FRATELLI ALITTI SOCIETA DI ESERCIZIO S.P.A. (IT) | 1999-10-12 | — | — | US | disclosed |
| EP-0906758-A1 | Zinc-phthalocyanines and corresponding conjugates, their preparation and use in photodynamic therapy and as diagnostic agents | MOLTENI L. & C. dei Fratelli Alitti Società di Esercizio S.P.A. (IT) | 1999-04-07 | — | — | EP | disclosed |
| WO-1999004895-A1 | COMPOSITIONS FOR THE STORAGE AND DELIVERY OF SOLID PHASE REACTIVE PARTICLES AND METHODS OF USING THE SAME | ARGONAUT TECHNOLOGIES, INC. (US) | 1999-02-04 | — | — | WO | disclosed |
| WO-1998051697-A2 | METHOD FOR PRODUCING POLYMERS HAVING NUCLEO-BASES AS SIDE-GROUPS | MORPHOCHEM AG (DE) | 1998-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230040236-A1 | Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications | MC1R, MC3R, MC5R | TAAR1 107/4885KDM4E 4794/4885LMNA 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.